A new report analyzing 2019 securities litigation suggests the volume of class actions and the size of their settlements will likely continue at high levels in upcoming years, especially in the already hard-hit pharmaceutical sector.

That’s the main takeaway for general counsel from the “Securities Class Action Settlements—2019 Review and Analysis,” according to Laura Simmons, the report’s co-author and a senior research adviser at Cornerstone Research.